HCPCS Service Codes - Medical care

HCPCS Codes for Medical care

• A2001

  Innovamatrix ac, per square centimeter

• A2002

  Mirragen advanced wound matrix, per square centimeter

• A2004

  Xcellistem, 1 mg

• A2005

  Microlyte matrix, per square centimeter

• A2006

  Novosorb synpath dermal matrix, per square centimeter

• A2007

  Restrata, per square centimeter

• A2008

  Theragenesis, per square centimeter

• A2009

  Symphony, per square centimeter

• A2010

  Apis, per square centimeter

• A2011

  Supra sdrm, per square centimeter

• A2012

  Suprathel, per square centimeter

• A2013

  Innovamatrix fs, per square centimeter

• A4100

  Skin substitute, fda cleared as a device, not otherwise specified

• A4216

  Sterile water, saline and/or dextrose, diluent/flush, 10 ml

• A4217

  Sterile water/saline, 500 ml

• A4218

  Sterile saline or water, metered dose dispenser, 10 ml

• A9581

  Injection, gadoxetate disodium, 1 ml

• C8957

  Intravenous infusion for therapy/diagnosis; initiation of prolonged infusion (more than 8 hours), requiring use of portable or implantable pump

• C9094

  Inj, sutimlimab-jome, 10 mg

• C9095

  Inj, tebentafusp-tebn, 1 mcg

• C9096

  Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram

• C9097

  Inj, faricimab-svoa, 0.1 mg

• C9098

  Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose

• C9121

  Injection, argatroban, per 5 mg

• C9132

  Prothrombin complex concentrate (human), kcentra, per i.u. of factor ix activity

• C9248

  Injection, clevidipine butyrate, 1 mg

• C9285

  Lidocaine 70 mg/tetracaine 70 mg, per patch

• C9290

  Injection, bupivacaine liposome, 1 mg

• C9293

  Injection, glucarpidase, 10 units

• C9399

  Unclassified drugs or biologicals

• C9460

  Injection, cangrelor, 1 mg

• C9738

  Adjunctive blue light cystoscopy with fluorescent imaging agent (list separately in addition to code for primary procedure)

• C9757

  Laminotomy (hemilaminectomy), with decompression of nerve root(s), including partial facetectomy, foraminotomy and excision of herniated intervertebral disc, and repair of annular defect with implantation of bone anchored annular closure device, including annular defect measurement, alignment and sizing assessment, and image guidance; 1 interspace, lumbar

• C9800

  Dermal injection procedure(s) for facial lipodystrophy syndrome (lds) and provision of radiesse or sculptra dermal filler, including all items and supplies

• C9898

  Radiolabeled product provided during a hospital inpatient stay

• C9899

  Implanted prosthetic device, payable only for inpatients who do not have inpatient coverage

• G0010

  Administration of hepatitis b vaccine

• G0028

  Documentation of medical reason(s) for not screening for tobacco use (e.g., limited life expectancy, other medical reason)

• G0029

  Tobacco screening not performed or tobacco cessation intervention not provided on the date of the encounter or within the previous 12 months, reason not otherwise specified

• G0030

  Patient screened for tobacco use and received tobacco cessation intervention on the date of the encounter or within the previous 12 months (counseling, pharmacotherapy, or both), if identified as a tobacco user

• G0031

  Palliative care services given to patient any time during the measurement period

• G0032

  Two or more antipsychotic prescriptions ordered for patients who had a diagnosis of schizophrenia, schizoaffective disorder, or bipolar disorder on or between january 1 of the year prior to the measurement period and the index prescription start date (ipsd) for antipsychotics

• G0033

  Two or more benzodiazepine prescriptions ordered for patients who had a diagnosis of seizure disorders, rapid eye movement sleep behavior disorder, benzodiazepine withdrawal, ethanol withdrawal, or severe generalized anxiety disorder on or between january 1 of the year prior to the measurement period and the ipsd for benzodiazepines

• G0034

  Patients receiving palliative care during the measurement period

• G0035

  Patient has any emergency department encounter during the performance period with place of service indicator 23

• G0036

  Patient or care partner decline assessment

• G0037

  On date of encounter, patient is not able to participate in assessment or screening, including non-verbal patients, delirious, severely aphasic, severely developmentally delayed, severe visual or hearing impairment and for those patients, no knowledgeable informant available

• G0038

  Clinician determines patient does not require referral

• G0039

  Patient not referred, reason not otherwise specified

• G0040

  Patient already receiving physical/occupational/speech/recreational therapy during the measurement period